Skip to main content
. 2021 May 21:1–12. doi: 10.1080/08923973.2021.1925293

Figure 2.

Figure 2.

Inhibitory effects of tranilast on inflammation, to manage COVID‐19. Studies have shown that SARS-CoV-2 elevates inflammation and activates NLRP3 inflammasome, which subsequently lead to a cytokine storm and destructive inflammation as well as causing ALI/ARDS in patients with COVID‐19. Tranilast can potentially play an effective role on the regulation of immune system, NLRP3 inflammasome, and inflammation, and provide support for Patients with both severe and moderate COVID‐19.